Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer

Gianluca Tedaldi, Michela Tebaldi, Valentina Zampiga, Rita Danesi, Valentina Arcangeli, Mila Ravegnani, Ilaria Cangini, Francesca Pirini, Elisabetta Petracci, Andrea Rocca, Fabio Falcini, Dino Amadori, Daniele Calistri

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

As new genes predisposing to breast (BC) and ovarian cancer (OC) are constantly emerging, the use of panels of genes analyzed by Next-Generation Sequencing (NGS) is increasing in clinical diagnostics. The identification of a large number of new germline mutations allows for deeper knowledge of cancer predisposition, although raising many questions about patient management. BC and OC patients recruited by our counseling service between 2012-2015 were included in this study. DNA was extracted from peripheral blood and a panel of 94 genes involved in hereditary tumors was analyzed by NGS. Patient clinical features of BC and OC and cancer family history were collected and compared to the patient genetic profile. A total of 255 women were analyzed, 57 of whom had a pathogenic mutation in BRCA1/2 genes, and 17 carried pathogenic mutations in other genes, such as PALB2, ATM, BRIP1, RAD51D, MSH6, PPM1D, RECQL4, ERCC3, TSC2, SLX4 and other Fanconi anemia genes. Patients with a pathogenic mutation in genes other than BRCA1 and BRCA2 showed no significant difference from the BRCA1/2-mutated carriers with respect to age at diagnosis and clinical features, suggesting that mutations in other genes could pose a high risk of cancer development. These patients had a much higher percentage of bilateral breast cancer (BBC) and a lower rate of OC than BRCA-mutated patients and patients with no pathogenic mutations: as a consequence, the surveillance protocol should be customized to the patient genetic characteristics.

Original languageEnglish
Pages (from-to)47064-47075
Number of pages12
JournalOncotarget
Volume8
Issue number29
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Ovarian Neoplasms
Breast Neoplasms
Genes
Mutation
BRCA1 Gene
Neoplasms
BRCA2 Gene
Fanconi Anemia
Germ-Line Mutation
Counseling
DNA

Keywords

  • Bilateral breast cancer
  • Cancer predisposition
  • Hereditary breast and ovarian cancer
  • Multiple-gene panel
  • Next-generation sequencing

ASJC Scopus subject areas

  • Oncology

Cite this

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. / Tedaldi, Gianluca; Tebaldi, Michela; Zampiga, Valentina; Danesi, Rita; Arcangeli, Valentina; Ravegnani, Mila; Cangini, Ilaria; Pirini, Francesca; Petracci, Elisabetta; Rocca, Andrea; Falcini, Fabio; Amadori, Dino; Calistri, Daniele.

In: Oncotarget, Vol. 8, No. 29, 01.01.2017, p. 47064-47075.

Research output: Contribution to journalArticle

Tedaldi, Gianluca ; Tebaldi, Michela ; Zampiga, Valentina ; Danesi, Rita ; Arcangeli, Valentina ; Ravegnani, Mila ; Cangini, Ilaria ; Pirini, Francesca ; Petracci, Elisabetta ; Rocca, Andrea ; Falcini, Fabio ; Amadori, Dino ; Calistri, Daniele. / Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. In: Oncotarget. 2017 ; Vol. 8, No. 29. pp. 47064-47075.
@article{28c2285c878e431eba2846a27898fa1e,
title = "Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer",
abstract = "As new genes predisposing to breast (BC) and ovarian cancer (OC) are constantly emerging, the use of panels of genes analyzed by Next-Generation Sequencing (NGS) is increasing in clinical diagnostics. The identification of a large number of new germline mutations allows for deeper knowledge of cancer predisposition, although raising many questions about patient management. BC and OC patients recruited by our counseling service between 2012-2015 were included in this study. DNA was extracted from peripheral blood and a panel of 94 genes involved in hereditary tumors was analyzed by NGS. Patient clinical features of BC and OC and cancer family history were collected and compared to the patient genetic profile. A total of 255 women were analyzed, 57 of whom had a pathogenic mutation in BRCA1/2 genes, and 17 carried pathogenic mutations in other genes, such as PALB2, ATM, BRIP1, RAD51D, MSH6, PPM1D, RECQL4, ERCC3, TSC2, SLX4 and other Fanconi anemia genes. Patients with a pathogenic mutation in genes other than BRCA1 and BRCA2 showed no significant difference from the BRCA1/2-mutated carriers with respect to age at diagnosis and clinical features, suggesting that mutations in other genes could pose a high risk of cancer development. These patients had a much higher percentage of bilateral breast cancer (BBC) and a lower rate of OC than BRCA-mutated patients and patients with no pathogenic mutations: as a consequence, the surveillance protocol should be customized to the patient genetic characteristics.",
keywords = "Bilateral breast cancer, Cancer predisposition, Hereditary breast and ovarian cancer, Multiple-gene panel, Next-generation sequencing",
author = "Gianluca Tedaldi and Michela Tebaldi and Valentina Zampiga and Rita Danesi and Valentina Arcangeli and Mila Ravegnani and Ilaria Cangini and Francesca Pirini and Elisabetta Petracci and Andrea Rocca and Fabio Falcini and Dino Amadori and Daniele Calistri",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16791",
language = "English",
volume = "8",
pages = "47064--47075",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "29",

}

TY - JOUR

T1 - Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer

AU - Tedaldi, Gianluca

AU - Tebaldi, Michela

AU - Zampiga, Valentina

AU - Danesi, Rita

AU - Arcangeli, Valentina

AU - Ravegnani, Mila

AU - Cangini, Ilaria

AU - Pirini, Francesca

AU - Petracci, Elisabetta

AU - Rocca, Andrea

AU - Falcini, Fabio

AU - Amadori, Dino

AU - Calistri, Daniele

PY - 2017/1/1

Y1 - 2017/1/1

N2 - As new genes predisposing to breast (BC) and ovarian cancer (OC) are constantly emerging, the use of panels of genes analyzed by Next-Generation Sequencing (NGS) is increasing in clinical diagnostics. The identification of a large number of new germline mutations allows for deeper knowledge of cancer predisposition, although raising many questions about patient management. BC and OC patients recruited by our counseling service between 2012-2015 were included in this study. DNA was extracted from peripheral blood and a panel of 94 genes involved in hereditary tumors was analyzed by NGS. Patient clinical features of BC and OC and cancer family history were collected and compared to the patient genetic profile. A total of 255 women were analyzed, 57 of whom had a pathogenic mutation in BRCA1/2 genes, and 17 carried pathogenic mutations in other genes, such as PALB2, ATM, BRIP1, RAD51D, MSH6, PPM1D, RECQL4, ERCC3, TSC2, SLX4 and other Fanconi anemia genes. Patients with a pathogenic mutation in genes other than BRCA1 and BRCA2 showed no significant difference from the BRCA1/2-mutated carriers with respect to age at diagnosis and clinical features, suggesting that mutations in other genes could pose a high risk of cancer development. These patients had a much higher percentage of bilateral breast cancer (BBC) and a lower rate of OC than BRCA-mutated patients and patients with no pathogenic mutations: as a consequence, the surveillance protocol should be customized to the patient genetic characteristics.

AB - As new genes predisposing to breast (BC) and ovarian cancer (OC) are constantly emerging, the use of panels of genes analyzed by Next-Generation Sequencing (NGS) is increasing in clinical diagnostics. The identification of a large number of new germline mutations allows for deeper knowledge of cancer predisposition, although raising many questions about patient management. BC and OC patients recruited by our counseling service between 2012-2015 were included in this study. DNA was extracted from peripheral blood and a panel of 94 genes involved in hereditary tumors was analyzed by NGS. Patient clinical features of BC and OC and cancer family history were collected and compared to the patient genetic profile. A total of 255 women were analyzed, 57 of whom had a pathogenic mutation in BRCA1/2 genes, and 17 carried pathogenic mutations in other genes, such as PALB2, ATM, BRIP1, RAD51D, MSH6, PPM1D, RECQL4, ERCC3, TSC2, SLX4 and other Fanconi anemia genes. Patients with a pathogenic mutation in genes other than BRCA1 and BRCA2 showed no significant difference from the BRCA1/2-mutated carriers with respect to age at diagnosis and clinical features, suggesting that mutations in other genes could pose a high risk of cancer development. These patients had a much higher percentage of bilateral breast cancer (BBC) and a lower rate of OC than BRCA-mutated patients and patients with no pathogenic mutations: as a consequence, the surveillance protocol should be customized to the patient genetic characteristics.

KW - Bilateral breast cancer

KW - Cancer predisposition

KW - Hereditary breast and ovarian cancer

KW - Multiple-gene panel

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85024364448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024364448&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16791

DO - 10.18632/oncotarget.16791

M3 - Article

AN - SCOPUS:85024364448

VL - 8

SP - 47064

EP - 47075

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -